Johnson & Johnson Makes New $89.72 Billion Investment in MeiraGTx Holdings PLC $MGTX

Johnson & Johnson acquired a new position in shares of MeiraGTx Holdings PLC (NASDAQ:MGTX) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 6,641,064 shares of the company’s stock, valued at approximately $89,720,775,000. MeiraGTx accounts for about 11.2% of Johnson & Johnson’s holdings, making the stock its 3rd largest holding. Johnson & Johnson owned approximately 0.07% of MeiraGTx at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in MGTX. BNP Paribas Financial Markets raised its stake in MeiraGTx by 43.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,810 shares of the company’s stock worth $31,000 after acquiring an additional 1,466 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in MeiraGTx by 390.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,797 shares of the company’s stock worth $57,000 after acquiring an additional 7,005 shares during the period. ProShare Advisors LLC purchased a new stake in MeiraGTx during the 4th quarter valued at about $94,000. Abel Hall LLC purchased a new stake in MeiraGTx during the 4th quarter valued at about $98,000. Finally, Bank of Nova Scotia acquired a new position in shares of MeiraGTx in the first quarter valued at about $105,000. 67.48% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at MeiraGTx

In other news, CFO Richard Giroux sold 56,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 21st. The shares were sold at an average price of $12.51, for a total transaction of $700,560.00. Following the sale, the chief financial officer owned 908,530 shares of the company’s stock, valued at $11,365,710.30. This trade represents a 5.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Stuart Naylor sold 27,659 shares of MeiraGTx stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $14.80, for a total transaction of $409,353.20. Following the transaction, the insider directly owned 640,846 shares of the company’s stock, valued at approximately $9,484,520.80. This trade represents a 4.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 145,659 shares of company stock worth $1,678,453. 7.40% of the stock is owned by corporate insiders.

MeiraGTx Stock Performance

Shares of MGTX opened at $13.52 on Friday. The business’s 50-day moving average is $12.09 and its two-hundred day moving average is $9.82. The company has a market capitalization of $1.25 billion, a P/E ratio of 19.04 and a beta of 1.23. MeiraGTx Holdings PLC has a fifty-two week low of $6.62 and a fifty-two week high of $15.35.

MeiraGTx (NASDAQ:MGTX) last issued its quarterly earnings data on Thursday, August 13th. The company reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $2.17. MeiraGTx had a negative return on equity of 226.79% and a net margin of 19.87%.The business had revenue of $321.43 million during the quarter, compared to analysts’ expectations of $0.70 million. Analysts forecast that MeiraGTx Holdings PLC will post -0.48 EPS for the current year.

Key Headlines Impacting MeiraGTx

Here are the key news stories impacting MeiraGTx this week:

• Positive Sentiment: RBC raised its price target to $27 from $26 and maintained an “outperform” rating. The new target implies substantial potential upside from the reported $13.52 trading level, providing a bullish signal from a major analyst. Benzinga
• Positive Sentiment: MeiraGTx reported second-quarter EPS of $1.71, significantly exceeding consensus expectations for a loss. Revenue reached $321.43 million versus an analyst estimate of approximately $0.70 million, and the company swung to a quarterly profit from a year-earlier loss. The magnitude of the beat is likely a key driver of the stock’s advance, though investors may assess how much of the results reflects recurring operations versus nonrecurring items. MeiraGTx Swings to Q2 Profit, Revenue Rises
• Positive Sentiment: The company received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year Phase 1 AQUAx data for radiation-induced dry mouth. It also acquired rights to bota-vec for X-linked retinitis pigmentosa and expects global regulatory filings in 2026, with a potential AAV2-hAQP1 BLA filing in mid-2027. MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
• Neutral Sentiment: A comparison of MeiraGTx with Biomea Fusion provides sector context but does not introduce a new company-specific catalyst. Head-To-Head Survey: Biomea Fusion and MeiraGTx
• Negative Sentiment: MeiraGTx funded the bota-vec acquisition with a $100 million equity financing, which may create shareholder dilution. However, the transaction also includes up to $400 million of strategic investment, including as much as $375 million in non-dilutive capital.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on MGTX shares. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of MeiraGTx in a research note on Wednesday, July 8th. Piper Sandler upped their target price on MeiraGTx from $26.00 to $30.00 and gave the company an “overweight” rating in a research report on Wednesday, April 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of MeiraGTx in a report on Friday, July 17th. Zacks Research raised shares of MeiraGTx from a “hold” rating to a “strong-buy” rating in a research report on Thursday. Finally, Royal Bank Of Canada lifted their price objective on shares of MeiraGTx from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Friday. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, MeiraGTx presently has a consensus rating of “Buy” and an average target price of $26.17.

MeiraGTx Company Profile

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.